Back

Direct inhibitors of factor XI/XIa: where are we now?

31 August 2026 (08:15 - 08:33)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: what is new and what is to come? Treatment ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Bianca Rocca

LUM University, Casamassima (Italy)

4 More presentations in this session

Presentation thumbnail
Left atrial appendage closure: integrating opposing trials
Professor U. Landmesser (Berlin, DE)
Slides Video
Presentation thumbnail
Antiarrhythmic drugs: any news yet?
Professor U. Ravens (Freiburg, DE)
Slides Video
Presentation thumbnail
Artificial intelligence-driven population screening for atrial fibrillation: ready for prime time?
Doctor P. Noseworthy (Rochester, US)
Slides Video
Presentation thumbnail
Atrial fibrillation: what is new and what is to come? - discussion
Video

Access the full session

Session thumbnail
Atrial fibrillation: what is new and what is to come?
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Shaping clinical practice and clinical trials
29 August 2025
thumbnail
Congress Presentation
Elevated factor XI is associated with left atrial appendage thrombi of unknown origin: links to unfavorable fibrin clot properties
1 September 2025
thumbnail
Congress Presentation
Activated factor XI is associated with recurrent venous thromboembolism in patients following pulmonary embolism: a cohort study
29 August 2026
thumbnail
Congress Presentation
Balancing safety and efficacy: Factor XIa inhibitors vs. DOACs in atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources